Converts 1-acyl-sn-glycerol-3-phosphate (lysophosphatidic acid or LPA) into 1,2-diacyl-sn-glycerol-3-phosphate (phosphatidic acid or PA) by incorporating an acyl moiety at the sn-2 position of the glycerol backbone. Acts on LPA containing saturated or unsaturated fatty acids C15:0-C20:4 at the sn-1 position using C18:1-CoA as the acyl donor. Also acts on lysophosphatidylethanolamine using oleoyl-CoA, but not arachidonoyl-CoA, and lysophosphatidylinositol using arachidonoyl-CoA, but not oleoyl-CoA. Activity toward lysophosphatidylglycerol not detectable.

Description
Rabbit polyclonal antibody to AGPAT5

Applications 
WB, IF, ICC, IHC.

Immunogen 
AGPAT5 Antibody detects endogenous levels of total AGPAT5.

Reactivity 
Human, Mouse.
可预测：Horse(86%), Dog(%)

Molecular weight
45 KD; 42kD(Calculated).

Host species 
Rabbit

Ig class 
Immunogen-specific rabbit IgG

Purification 
Antigen affinity purification

Full name 
AGPAT5

Synonyms 
1 acyl sn glycerol 3 phosphate acyltransferase epsilon; 1 acylglycerol 3 phosphate O acyltransferase 5; 1 AGP acyltransferase 5; 1 AGPAT 5; 1 AGPAT5; 1-acyl-sn-glycerol-3-phosphate acyltransferase epsilon; 1-acylglycerol-3-phosphate O-acyltransferase 5 (lysophosphatidic acid acyltransferase, epsilon); 1-acylglycerol-3-phosphate O-acyltransferase 5; 1-AGP acyltransferase 5; 1-AGPAT 5; 1acylglycerol3phosphate Oacyltransferase 5 (lysophosphatidic acid acyltransferase, epsilon); 1acylglycerol3phosphate Oacyltransferase 5; 1acylglycerol3phosphate Oacyltransferase5 (lysophosphatidic acid acyltransferase, epsilon); 1AGP acyltransferase 5; 1AGPAT5; AGPAT5; LPAAT e; LPAAT epsilon; LPAAT-epsilon; LPAATE; Lysophosphatidic acid acyltransferase epsilon; PLCE_HUMAN;

Storage
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.

Swissprot 
Q9NUQ2

Western blot analysis of extracts from Mouse liver, using AGPAT5 Antibody. The lane on the left was treated with blocking peptide....

Western blot analysis of extracts from Hela, using AGPAT5 Antibody....

ab14500 at 1/100 staining Human pancreatic cancer and adjacent nomal tissues by IHC-P. The sample was formaldehyde fixed and a heat mediated antigen retrieval step in citrate buffer was performed. The sample was then blocked and incubated with the primary antibody at 4°C overnight. An HRP conjugated anti-Rabbit antibody was used as the secondary antibody....

Figure 8 Preliminary validation of AGPAT5, LCLAT1, and LPCAT1. (A) Immunohistochemistry of HCC tumor tissues and adjacent normal tissues. (B–D) CCK-8 assay (B), migration assay (C), and invasion assay (D) after knockdown of AGPAT5, LCLAT1, and LPCAT1 in HepG2 using siRNA and non-targeted control siRNA, respectively. (E) Western blotting validation of knockdown efficacy after transfection of HepG2 using siRNA and non-targeting control siRNA. (F) Validation of common tumor-associated protein markers after knockdown of AGPAT5. (G) Validation of common tumor-associated protein markers after knockdown of LCLAT1. (H) Validation of common tumor-associated protein markers after knockdown of LPCAT1. Representative images are shown. Magnification 100x; scale bar: 200 μm. Significance signs:...

Figure 8 Preliminary validation of AGPAT5, LCLAT1, and LPCAT1. (A) Immunohistochemistry of HCC tumor tissues and adjacent normal tissues. (B–D) CCK-8 assay (B), migration assay (C), and invasion assay (D) after knockdown of AGPAT5, LCLAT1, and LPCAT1 in HepG2 using siRNA and non-targeted control siRNA, respectively. (E) Western blotting validation of knockdown efficacy after transfection of HepG2 using siRNA and non-targeting control siRNA. (F) Validation of common tumor-associated protein markers after knockdown of AGPAT5. (G) Validation of common tumor-associated protein markers after knockdown of LCLAT1. (H) Validation of common tumor-associated protein markers after knockdown of LPCAT1. Representative images are shown. Magnification 100x; scale bar: 200 μm. Significance signs:...